血浆致动脉粥样硬化指数与高血压发病风险关联性的前瞻性动态队列研究

doi:10.13481/j.1671-587X.20260120

Abstract

Abstract:

Objective To explore the association between atherogenic index of plasma （AIP） and the risk of hypertension， and to clarify the application value of AIP as a risk predictor for hypertension. Methods The subjects were derived from a prospective cohort population established using a multi-stage stratified cluster sampling method. Based on the AIP quartiles， the included subjects were divided into four groups （Q1 group， Q2 group， Q3 group， and Q4 group）. The association between AIP and the risk of hypertension was explored using the Cox regression model， and subgroup analysis and interaction tests were employed to assess gender and age differences in this association. Results A total of 2 532 subjects were included in this study （632 in Q1 group， 634 in Q2 group， 633 in Q3 group， and 633 in Q4 group）. The median follow-up time was 4.69 years， and 1 587 subjects eventually developed hypertension （the incidence rate was 62.68%）. Compared with Q1， Q2， and Q3 groups， the male proportion in Q4 group was 35.70%， and a smoking proportion was 36.90%； the body mass index（BMI） and fasting plasma glucose（FPG） levels （P<0.001）. Based on a cohort study and multiple factor Cox regression model analysis， compared with Q1 group， the risk of hypertension in Q4 groups was increased by 24% ［hazard ratio（HR）=1.24， 95% confidence interval （CI）=1.07-1.44， P=0.004］. The interaction test results and subgroup analysis showed that there was an interaction between age and gender and AIP （P<0.05）； in the female population （HR=1.42， 95%CI=1.16-1.73， P=0.001） and<60 year old population （HR=1.31， 95%CI=1.11-1.54， P=0.001）， high AIP was a risk factor for developing hypertension. Conclusion An elevated AIP is associated with a higher risk of hypertension， particularly in the female and<60 year old populations where a higher AIP is closely related to the occurrence of hypertension.

Key words: Hypertension, Atherogenic index of plasma, Prospective cohort study, Predictive index, Cox regression model

CLC Number:

R181

Jinli YAN,Tao YAN,Yuan SHEN,Xingyue QI,Nan ZHANG,Hailing LI,Chunfa ZHANG,Lei XU,Han BAO,Xingguang ZHANG. Prospective dynamic cohort study on correlation between atherogenic index of plasma and risk of hypertension[J].Journal of Jilin University(Medicine Edition), 2026, 52(1): 192-198.

Figures/Tables 5

Fig. 1

Tab.1

Tab.2

Tab.3

Tab.4

References 26

[1]	SCHUTTE A E， JAFAR T H， POULTER N R， et al. Addressing global disparities in blood pressure control： perspectives of the International Society of Hypertension［J］. Cardiovasc Res， 2023， 119（2）： 381-409.
[2]	ZHOU B， PEREL P， MENSAH G A， et al. Global epidemiology， health burden and effective interventions for elevated blood pressure and hypertension［J］. Nat Rev Cardiol， 2021， 18（11）： 785-802.
[3]	NEUROLOGY T L. The global challenge of hypertension［J］. Lancet Neurol， 2023， 22（12）： 1087.
[4]	MILLS K T， STEFANESCU A， HE J. The global epidemiology of hypertension［J］. Nat Rev Nephrol， 2020， 16（4）： 223-237.
[5]	ZHANG M， SHI Y， ZHOU B， et al. Prevalence， awareness， treatment， and control of hypertension in China， 2004-18： findings from six rounds of a national survey［J］. BMJ， 2023， 380： e071952.
[6]	LIU J. Highlights of the 2018 Chinese hypertension guidelines［J］. Clin Hypertens， 2020， 26： 8.
[7]	KOSTOVA D， SPENCER G， MORAN A E，et al. The cost-effectiveness of hypertension management in low-income and middle-income countries： a review［J］. BMJ Glob Health，2020，5（9）：e002213.
[8]	LU M K， LI D X， HU Y L， et al. Persistence of severe global inequalities in the burden of hypertension heart disease from 1990 to 2019： findings from the global burden of disease study 2019［J］. BMC Public Health， 2024， 24（1）： 110.
[9]	TEO K K， RAFIQ T. Cardiovascular risk factors and prevention： a perspective from developing countries［J］. Can J Cardiol， 2021， 37（5）： 733-743.
[10]	MANGIONE C M， BARRY M J， NICHOLSON W K，et al. Statin use for the primary prevention of cardiovascular disease in adults： us preventive services task force recommendation statement［J］. JAMA，2022，328（8）：746-753.
[11]	BALLARD-HERNANDEZ J， SALL J. Dyslipidemia update［J］. Nurs Clin N Am， 2023， 58（3）： 295-308.
[12]	ABID H， ABID Z， ABID S. Atherogenic indices in clinical practice and biomedical research： a short review［J］. Baghdad J Biochem Appl Biol Sci， 2021， 2（2）： 60-70.
[13]	FENG X X， LIU Y， YANG J Q， et al. The combined predictive power of the atherogenic index of plasma and serum glycated albumin for cardiovascular events in postmenopausal patients with acute coronary syndrome after percutaneous coronary intervention［J］. Lipids Health Dis， 2024， 23（1）： 352.
[14]	TAN M J， ZHANG Y L， JIN L， et al. Association between atherogenic index of plasma and prehypertension or hypertension among normoglycemia subjects in a Japan population： a cross-sectional study［J］. Lipids Health Dis， 2023， 22（1）： 87.
[15]	YUAN Y， SHI J， SUN W， et al. The positive association between the atherogenic index of plasma and the risk of new-onset hypertension： a nationwide cohort study in China［J］. Clin Exp Hypertens， 2024， 46（1）： 2303999.
[16]	CHENG W K， ZHUANG J Q， CHEN S W. Dyslipidemia and the prevalence of hypertension： a cross-sectional study based on Chinese adults without type 2 diabetes mellitus［J］. Front Cardiovasc Med， 2022， 9： 938363.
[17]	LU J P， XUAN S， DOWNING N S， et al. Protocol for the China PEACE （patient-centered evaluative assessment of cardiac events） million persons project pilot［J］. BMJ Open， 2016， 6（1）： e010200.
[18]	OATES J C， RUSSELL D L， VAN BEUSECUM J P. Endothelial cells： potential novel regulators of renal inflammation［J］. Am J Physiol Renal Physiol， 2022， 322（3）： F309-F321.
[19]	LIU R F， CHENG W L. Association between HDL-C and intensive blood pressure control in patients with hypertension： a post-hoc analysis of SPRINT［J］. J Clin Hypertens （Greenwich）， 2024， 26（3）： 225-234.
[20]	LEI X T， QIU S， YANG G Y， et al. Adiponectin and metabolic cardiovascular diseases： Therapeutic opportunities and challenges［J］. Genes Dis， 2023， 10（4）： 1525-1536.
[21]	HONG X S， ZHANG X Y， YOU L L， et al. Association between adiponectin and newly diagnosed type 2 diabetes in population with the clustering of obesity， dyslipidaemia and hypertension： a cross-sectional study［J］. BMJ Open， 2023， 13（2）： e060377.
[22]	CHEN L， FUKUDA N， MATSUMOTO T， et al. Role of complement 3 in the pathogenesis of hypertension［J］. Hypertens Res， 2020， 43（4）： 255-262.
[23]	WENZEL U O， KEMPER C， BODE M. The role of complement in arterial hypertension and hypertensive end organ damage［J］. Br J Pharmacol， 2021， 178（14）： 2849-2862.
[24]	ONAT A， CAN G， KAYA H， et al. “Atherogenic index of plasma” （log10 triglyceride/high-density lipoprotein-cholesterol） predicts high blood pressure， diabetes， and vascular events［J］. J Clin Lipidol， 2010， 4（2）： 89-98.
[25]	LIU Y H， ZHU B B， ZHOU W C， et al. Triglyceride-glucose index as a marker of adverse cardiovascular prognosis in patients with coronary heart disease and hypertension［J］. Cardiovasc Diabetol， 2023， 22（1）： 133.
[26]	DASTMALCHI L N， GERMAN C A， TAUB P R. High density lipoprotein： When to rethink too much of a good thing［J］. Am J Prev Cardiol， 2023， 15： 100511.

Variable	AIP quartile array				χ²	P
Variable	Q1 (<-0.18)	Q2 (-0.18-0.02)	Q3 (0.02-0.25)	Q4 (≥0.25)	χ²	P
Number of people	632	634	633	633
Gender[n(%)]
Male	185(19.96)	186(20.06)	225(24.27)	331(35.71)	96.49	<0.001
Female	447(27.85)	448(27.91)	408(25.42)	302(18.82)	96.49	<0.001
Age(year) [n(%)]
<60	524(25.47)	504(24.50)	509(24.75)	520(25.28)	3.05	0.383
≥60	108(22.74)	130(27.37)	124(26.10)	113(23.79)	3.05	0.383
Smoking [n(%)]
Yes	122(18.07)	140(20.74)	164(24.30)	249(36.89)	76.49	<0.001
No	510(27.46)	494(26.60)	469(25.26)	384(20.68)	76.49	<0.001
Drinking [n(%)]
Yes	54(34.18)	28(17.72)	26(16.45)	50(31.65)	17.24	<0.001
No	578(24.35)	606(25.52)	607(25.57)	583(24.56)	17.24	<0.001
Family history of illness [n(%)]
Yes	568(26.87)	530(25.07)	516(24.41)	500(23.65)	29.78	<0.001
No	64(15.31)	104(24.88)	117(27.99)	133(31.82)
BMI[n(%)]
<24 kg·m^-2	432(38.71)	300(26.88)	228(20.43)	156(13.98)	267.47	<0.001
≥24 kg·m^-2	200(14.12)	334(23.59)	405(28.60)	477(33.69)	267.47	<0.001

Variable	AIP quartile array				F	P
Variable	Q1 (<-0.18)	Q2 (-0.18-0.02)	Q3 (0.02-0.25)	Q4 (≥0.25)	F	P
Number of people	632	634	633	633
TC[c_B/(mmol·L^-1)]	4.64±1.20	4.78±1.28	4.90±1.49	4.67±1.35	10.66	0.014
FPG[c_B/(mmol·L^-1)]	5.74±1.20	5.92±1.30	6.15±1.63	6.38±1.76	101.90	<0.001
LDL-c[c_B/(mmol·L^-1)]	2.63±1.04	2.89±1.15	3.05±1.28	2.81±1.25	13.18	<0.001

AIP Quartile array	Unadjusted		Model 1	Model 2			Model 3
AIP Quartile array	HR （95%CI）	P	HR （95%CI）	P	HR （95%CI）	P	HR （95%CI）	P
Q1 (<-0.18)	1.00		1.00		1.00		1.00
Q2 (-0.18-0.02)	1.12(0.97-1.30)	0.124	1.10(0.95-1.27)	0.216	1.09(0.94-1.27)	0.251	1.09(0.94-1.25)	0.260
Q3 (0.02-0.25)	1.30(1.13-1.51)	<0.001	1.27(1.10-1.47)	0.001	1.27(1.09-1.47)	0.002	1.25(1.08-1.44)	0.002
Q4 (≥0.25)	1.29(1.11-1.50)	0.001	1.24(1.07-1.45)	0.006	1.22(1.04-1.44)	0.015	1.24(1.07-1.44)	0.004

Group	AIP	Unadjusted		Adjusted^a
Group	AIP	HR（95%CI）	P	HR（95%CI）	P
Gender
Male
	Q1 (<-0.18)	1.00		1.00
	Q2 (-0.18-0.02)	1.01(0.80-1.30)	0.909	0.99(0.77-1.28)	0.944
	Q3 (0.02-0.25)	1.06(0.83-1.34)	0.656	1.05(0.83-1.34)	0.673
	Q4 (≥0.25)	0.98(0.79-1.22)	0.876	1.03(0.82-1.29)	0.801
Female
	Q1 (<-0.18)	1.00		1.00
	Q2 (-0.18-0.02)	1.18(1.00-1.41)	0.056	1.13 (0.95-1.34)	0.168
	Q3 (0.02-0.25)	1.43 (1.21-1.71)	<0.001	1.33(1.12-1.60)	0.001
	Q4 (≥0.25)	1.56(1.29-1.88)	<0.001	1.42(1.16-1.73)	0.001
Age(year)
<60
	Q1 (<-0.18)	1.00		1.00
	Q2 (-0.18-0.02)	1.14(0.97-1.34)	0.100	1.12(0.95-1.31)	0.181
	Q3 (0.02-0.25)	1.37(1.17-1.60)	<0.001	1.31(1.11-1.54)	0.001
	Q4 (≥0.25)	1.39(1.20-1.63)	<0.001	1.31(1.11-1.54)	0.001
≥60
	Q1 (<-0.18)	1.00		1.00
	Q2 (-0.18-0.02)	0.96(0.71-1.29)	0.767	0.93(0.68-1.26)	0.622
	Q3 (0.02-0.25)	1.07(0.78-1.45)	0.689	1.04(0.76-1.43)	0.819
	Q4 (≥0.25)	1.03(0.75-1.42)	0.845	0.99(0.71-1.39)	0.971

Prospective dynamic cohort study on correlation between atherogenic index of plasma and risk of hypertension

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 26

Related Articles 15

Metrics

Comments

Recommended 0

[1]	Li ZHANG,Binfeng XIA,Huihui HUANG,Ru WANG,Min KONG,Xia YIN. Research progress in pathophysiological mechanism and clinical diagnosis and treatment of hypertension associated with vascular endothelial growth factor and its receptor inhibitors [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 854-863.
[2]	Guanfei LI,Xunjuan ZHANG,Meng PANG,Song LI. Prospective study on association between hemodynamic patterns and risk of ischemic stroke in people with chronic orthostatic intolerance [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 473-480.
[3]	Shuhua YU,Wei LIU,Qianqian WU,Dongwei YANG. Effect of crocetin on vascular endothelial dysfunction and atherosclerosis in spontaneously hypertensive rats and its ROCK/JNK signaling pathway mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1481-1489.
[4]	Cong LI,Kun ZHAO,Jingliang ZHANG,Yingjie ZHANG,Hongxin WNAG. Protective effect of astragalus polysaccharides on pulmonary artery vessels in rats with MCT-induced pulmonary hypertension and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(6): 1371-1379.
[5]	Yue CHEN,Lei YU,Xiaoxin LAN,Siqi JIA,Haibo Yuan. Effects of deoxygenation and reoxygenation speeds on diurnal and nocturnal blood pressure in obstructive sleep apnea patients [J]. Journal of Jilin University(Medicine Edition), 2021, 47(4): 1008-1013.
[6]	CHEN Lin, ZHAO Liangzhi, CAI Yanjun, QI Yue, LI Wanyu. Liver transplantation for congenital hepatic fibrosis-induced liver function failure: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2020, 46(01): 159-163.
[7]	QIAN Chuyue, SONG Junli, LIU Naimeng, SUN Mindan. Influence of rifampin in effectiveness of antihypertensive drugs in patients with hypertension: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 418-421.
[8]	XIE Wenjie, LONG Haiquan, SONG Daifu, OU Dejin, JIANG Lan, CHEN Ximing, HUANG Jionghua. Level of autophagy-related protein-9a in plasma of hypertension patients with left ventricular hypertrophy and its clinical significance [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 786-790.
[9]	JIN Runhao, XU Zhongfu, LI Qing, QUAN Zhenyu, HAN Chunji. Application of blood pressure-to-height ratioin screening adolescents' hypertension in Yanjicity of Jilin province [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 639-645.
[10]	LAN Yonghong, RAO Langyu, YANG Zhi, HUANG Mingmei, NIU Haiyan, QI Yaling. Expressions of HIF-1α and HSP70 in placenta tissue of patients withpregnancy-induced hypertension syndrome and their significances [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 346-349.
[11]	WANG Zhiguo, LIU Xueming, TONG Shengquan, SHI Zhequn, RAO Li. Therapeutic effect of mesenchymal stem cell transplantation on pulmonary hypertension in rats [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 21-25.
[12]	ZHOU Ye, CHENG Yunzhang, HUANG Jingyuan. Characteristics of left atrial function real-time three plane strain rate imaging in patients with hypertension and coronary artery stenosisand their significances [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 1019-1023.
[13]	ZHAO Tongyin, CHU Yunsong, ZHAO Huizi, LIU Zhiming, CAO Ning, LI Zhongmin. Survey analysis on relationship between dietary patterns and hypertension of residents in rural areas of Jilin Province [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 400-404.
[14]	XU Lisi, HE Jinting, MANG Jing, WANG Xueju, WANG Liping, NA Wanli, SHAO Yankun, XU Zhongxin. Pheochromocytoma with headache as first symptom: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2015, 41(05): 1027-1031.
[15]	JIANG Lingling, YANG Xueling, LYU Wei, ZHANG Yue, YIN Yutian, WANG Yuhan, WANG Rui, ZHANG Peng, LI Bo, YAO Yan. Association between HLA-DRB1 gene polymorphisms and essential hypertension [J]. Journal of Jilin University Medicine Edition, 2015, 41(03): 619-624.